Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why Shares of Immune Pharmaceuticals (IMNP) Are Off the Charts on Thursday

Shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) leaped through the charts by 48.70% to $3.63 midday on April 20, after announcing its entry into a letter of intent with pharma company Pint Pharma GmnH to give the latter exclusive rights to commercialize Ceplene throughout Latin America. “Adding Ceplene to our portfolio of products will further leverage our experience and presence in the oncology field in Latin America,” Pint CEO David Munoz said. “We are delighted to potentially have Immune as a committed partner to help strengthen our product portfolio.”

In conjunction with the anticipated final agreement, Pint will make an investment of $4 million into Immune Pharma’s oncology subsidiary, Cytovi, Inc. to be used by Cytovia exclusively for oncology related activities. Ceplene has been approved in Europe for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML) in combination with interleukin-2 (IL-2). According to Pint, there are approximately 10,000 new cases of AML diagnosed per year in Latin America and there is currently no approved treatment for the maintenance of  AML remission.

Traders flocked the company’s shares today as we saw trading volume at 16.7 million shares traded, compared to its average volume of $2.8 million as of press time.



What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

None of the 742 funds we track hold shares if Immune Pharmaceuticals Inc. (NASDAQ:IMNP). The company has a market capitalization of $34.41 million, and it currently stands on the upper end of its 52-week range high.

The Bottom Line

Traders are flocking Immune Pharmaceuticals Inc. (NASDAQ:IMNP) after entering into a letter of intent pharma company Pint Pharma GmnH to give the latter exclusive rights to commercialize Ceplene throughout Latin America. For further reading, here are the 10 least competitive pharmacy schools in America.

Follow Immune Pharmaceuticals Inc (NASDAQ:IMNPQ)


DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.